Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2018 | Moderna Therapeutics | Series G | 0 |
10/2021 | Deka Biosciences | Series A | 0 |
7/2020 | Vesigen Therapeutics | Series A | 28.5M |
12/2017 | Obsidian Therapeutics | Series A | 0 |
3/2018 | Prevail Therapeutics | Series A | 75M |
9/2021 | Acrigen Biosciences | Seed Round | - |
10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
1/2022 | Avalo | Convertible Note | 750k |
6/2022 | Dren Bio | Series B | 0 |
7/2020 | Vor Biopharma | Series B | 0 |
10/2018 | Stoke Therapeutics | Series B | 90M |
4/2021 | Alloy Therapeutics | Series C | 75M |
4/2021 | SeQure DX | Series A | 0 |
7/2019 | X-Vax Technology | Series A | 0 |
10/2019 | Molecular Assemblies | Series A | 0 |
12/2021 | Meiogenix | Series A | 12.4M |
1/2021 | Myeloid Therapeutics | Series A | 50M |
1/2021 | Encodia | Series C | 75M |
9/2022 | Novome | Series B | 0 |
4/2017 | Arsanis | Series D | 0 |
1/2019 | Frequency Therapeutics | Series B | - |
7/2021 | Wugen | Series B | 0 |
9/2018 | Epic Sciences | Series E | 0 |
3/2018 | IDEAYA Biosciences | Series B | 0 |
1/2019 | Immusoft | Series B | 0 |
10/2022 | Odyssey Therapeutics | Series B | 0 |
5/2022 | Pleno | Seed Round | 0 |
1/2020 | TwinStrand Biosciences | Series A | 16M |
3/2022 | Umaro Foods | Seed Round | 0 |
3/2022 | Eclipse Bioinnovations | Series A | 14M |
4/2022 | Pheast Therapeutics | Series A | 0 |
10/2021 | Immunai | Series B | 215M |
5/2021 | Inari | Series D | 0 |
8/2021 | Humacyte | PIPE | 175M |
4/2023 | Function Oncology | Series A | 28M |
6/2021 | TRex Bio | Series A | 59M |
5/2021 | Invaio Sciences | Series C | 88.9M |
3/2019 | Cardea Bio | Series A | 7.8M |
10/2021 | Crop Enhancement | Convertible Note | - |
9/2021 | LEXEO Therapeutics | Series B | 0 |
12/2017 | Aura Biosciences | Series C | 0 |
1/2020 | Novome Biotechnologies | Series A | 0 |
9/2021 | Kytopen | Series A | 0 |
8/2021 | Immunitas Therapeutics | Series B | 0 |
9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
9/2018 | BlueLight Therapeutics | Series C | 20M |
5/2018 | Celsius Therapeutics | Series A | 65M |
9/2020 | Korro Bio | Series A | 0 |
11/2021 | Parthenon Therapeutics | Series A | 0 |
12/2018 | Kallyope | Series B | 21M |
3/2017 | Boragen | Series A | 10M |
12/2019 | Aspen Neuroscience | Seed Round | 0 |
8/2018 | Inari | Series B | 40M |
7/2022 | Cartography Biosciences | Series A | 0 |
7/2022 | Ozette Technologies | Series A | 0 |
6/2019 | Encoded Therapeutics | Series C | 104M |
11/2022 | Haystack Oncology | Series A | 56M |
2/2022 | Harpe Bio | Convertible Note | 3.2M |
3/2019 | Gencove | Seed Round | 3M |
9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
6/2021 | Bright Peak Therapeutics | Series B | 107M |
1/2021 | LEXEO Therapeutics | Series A | 0 |
8/2021 | Thryv Therapeutics | Series A | 0 |
3/2017 | EGenesis | Series A | 0 |
12/2020 | Faze Medicines | Series A | 81M |
7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
2/2022 | Harpe Bio | Venture Round | 3M |
7/2021 | Deep Genomics | Series C | 0 |
2/2023 | Paratus Sciences | Series A | 0 |
7/2017 | Rodeo Therapeutics | Series A | 5.9M |
6/2021 | ImmuneID | Series A | 0 |
3/2019 | Karuna Therapeutics | Series B | 0 |
6/2020 | Autobahn Therapeutics | Series B | 76M |
4/2023 | Orbital Therapeutics | Series A | 0 |
12/2022 | SonoThera | Series A | 0 |
11/2021 | Fountain Therapeutics | Series A | 0 |
7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
11/2018 | Caraway Therapeutics | Series A | 23M |
3/2020 | Kallyope | Series C | 112M |
11/2021 | Nitrase Therapeutics | Series A | 0 |
5/2018 | Insitro | Series A | 100M |
5/2022 | Remix Therapeutics | Series B | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
10/2017 | Visterra | Series C | 0 |
12/2019 | Jasper Therapeutics | Series A | 35M |
11/2021 | GeneCentric Therapeutics | Series B | 0 |
6/2018 | StrideBio | Series A | 15.7M |
5/2023 | Ten63 Therapeutics | Series A | 0 |
10/2017 | Cydan | Venture Round | 34M |
6/2018 | Precision BioSciences | Series B | 0 |
2/2019 | Applied Therapeutics | Series B | 0 |
7/2017 | Evelo Biosciences | Series B | 50M |
7/2019 | GNS Healthcare | Series D | 23M |
9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
3/2022 | Creyon Bio | Series A | 0 |
9/2018 | MouSensor | Seed Round | 3.3M |
7/2021 | IgGenix | Series A | 0 |
9/2018 | OncoResponse | Series B | 40M |
6/2020 | Element Biosciences | Series B | 30M |
4/2021 | Molecular Assemblies | Series A | 0 |
1/2019 | Dewpoint Therapeutics | Series A | 60M |
10/2019 | Verseau Therapeutics | Equity | 50M |
12/2020 | Remix Therapeutics | Series A | 65M |
4/2021 | Ventus Therapeutics | Series B | 100M |
11/2019 | Genetron Health | Series D | 71M |
1/2021 | AltPep | Series A | 23.1M |
6/2023 | AltPep | Series B | 0 |
10/2022 | Matchpoint Therapeutics | Series A | 70M |
11/2017 | Codiak Biosciences | Series C | 76.5M |
4/2018 | QurAlis | Seed Round | - |
1/2017 | Halio | Series C | 65M |
2/2017 | Applied Therapeutics | Series A | 6.1M |
9/2018 | ENB Therapeutics | Series A | 8.1M |
5/2018 | Nohla Therapeutics | Series B | 45M |
5/2021 | Marvin | Seed Round | 0 |
1/2023 | Melonfrost | Seed Round | 7M |
2/2023 | Garuda Therapeutics | Series B | 0 |
7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
9/2019 | Boundless Bio | Series A | 46.4M |
11/2019 | miRecule | Seed Round | 0 |
10/2021 | IpiNovyx Bio | Seed Round | 0 |
5/2021 | miRecule | Venture Round | 0 |
10/2021 | Soli Organic | Venture Round | 0 |
1/2019 | Greenlight Biosciences | Venture Round | 50M |
9/2020 | Sonoma BioTherapeutics | Series A | 0 |
7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
10/2021 | DNA Script | Series C | 0 |
3/2022 | Affini-T Therapeutics | Venture Round | 0 |
3/2017 | Antiva Biosciences | Series C | 22M |
12/2021 | Ambys Medicines | Series A | 47M |
9/2018 | Silverback Therapeutics | Series A | 37.5M |
11/2018 | Ribometrix | Series A | 30M |
1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
11/2022 | Cajal Neuroscience | Series A | 96M |
5/2021 | TwinStrand Biosciences | Series B | 50M |
6/2018 | Cibus | Series C | 70M |
4/2020 | Nitrase Therapeutics | Series A | 38M |
2/2021 | Ensoma | Series A | 0 |
6/2021 | Senda Biosciences | Series B | 0 |
4/2019 | Insitro | Series A | 100M |
9/2021 | Disc Medicine | Post-IPO Equity | 0 |
9/2021 | Disc Medicine | Series B | 90M |
3/2019 | Prevail Therapeutics | Series B | 50M |
1/2018 | Expansion Therapeutics | Series A | 55.3M |
9/2021 | Asher Bio | Series B | 0 |
3/2019 | Imara | Series B | 0 |
9/2022 | Capstan Therapeutics | Series A | 102M |
9/2021 | Lycia Therapeutics | Series B | 70M |
6/2021 | Mnemo Therapeutics | Series A | 90M |
10/2019 | Variant Bio | Series A | 24.7M |
7/2018 | Antiva Biosciences | Series C | 15M |
5/2022 | MOMA Therapeutics | Series B | 0 |
9/2021 | ROME Therapeutics | Series B | 0 |
6/2021 | Veralox Therapeutics | Series A | 0 |
7/2018 | ORIG3N | Series B | 0 |
5/2023 | Myeloid Therapeutics | Series B | 0 |
8/2018 | Magnolia NeuroSciences | Series A | 0 |
4/2019 | Arrakis Therapeutics | Series B | 75M |
6/2021 | Neurona Therapeutics | Venture Round | 0 |
12/2020 | Vigil Neuroscience | Series A | 50M |
5/2023 | Myeloid Therapeutics | Series A | 0 |
5/2021 | Soteria Biotherapeutics | Series A | 42M |
5/2021 | BioTheryX | Series E | 92M |
10/2020 | Dren Bio | Series A | 0 |
10/2017 | Ribometrix | Seed Round | 7.5M |
1/2021 | Blacksmith Medicines | Seed Round | - |
8/2022 | Senda Biosciences | Series C | 123M |
5/2021 | Advanced Animal Diagnostics | Series E | 0 |
3/2021 | StrideBio | Series B | 0 |
3/2020 | Redpin Therapeutics | Series A | 15.5M |
7/2017 | Compass Therapeutics, Inc. | Series A | - |
1/2023 | Ensoma | Series B | 0 |
3/2018 | TCR2 | Series B | 0 |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
12/2017 | Metacrine | Series B | 22M |
3/2022 | TRex Bio | Series A | 0 |
5/2022 | Aspen Neuroscience | Series B | 0 |
1/2021 | Dice Therapeutics | Series C | 80M |
2/2022 | Kallyope | Series D | 0 |
11/2021 | Acrivon Therapeutics | Series B | 0 |
1/2021 | Senti Biosciences | Series B | 105M |
12/2021 | NextVivo | Venture Round | 7.9M |
2/2018 | Quentis | Series A | 48M |
1/2022 | Korro Bio | Series B | 0 |
2/2022 | Ventus Therapeutics | Series C | 0 |
12/2022 | Dantari | Series A | 0 |
12/2020 | RayzeBio | Series B | 105M |
6/2022 | DEM BioPharma | Series A | 0 |
6/2023 | Bitterroot Bio | Series A | 0 |
1/2019 | Tiburio Therapeutics | Series A | 31M |
3/2020 | Affinia Therapeutics | Series A | 0 |
10/2021 | Neumora Therapeutics | Series A | 0 |
8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
7/2017 | Effector Therapeutics | Series C | 38.6M |
9/2017 | Gritstone Bio | Series B | 93M |
12/2019 | ImCheck Therapeutics | Series B | 53.2M |
9/2018 | Benson Hill | Series C | 65M |
3/2022 | Celsius Therapeutics | Series B | 0 |
6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
2/2022 | Terray Therapeutics | Series A | 0 |
7/2022 | Xilis | Series A | 0 |
6/2021 | RayzeBio | Series C | 108M |
6/2019 | BlackThorn Therapeutics | Series B | 76M |
3/2020 | Silverback Therapeutics | Series B | 0 |
4/2021 | Boundless Bio | Series B | 105M |
4/2020 | MOMA Therapeutics | Series A | 86M |
5/2023 | Boundless Bio | Series C | 0 |
9/2018 | System1 Biosciences | Series A | 25M |
11/2022 | Rezo | Series A | 0 |
1/2021 | Vera Therapeutics | Series C | 0 |
3/2021 | Insitro | Series C | 400M |
2/2019 | Maze Therapeutics | Series A | 191M |
11/2021 | Antiva Biosciences | Series D | 0 |
3/2023 | Chroma Medicine | Series B | 0 |
11/2018 | NextCure | Series B | 93M |
2/2018 | Kallyope | Series B | 66M |
10/2021 | Mozart Therapeutics | Series A | 0 |
7/2022 | Ozette Technologies | Series A | 0 |
7/2022 | Cartography Biosciences | Series A | 0 |
7/2022 | Xilis | Series A | 0 |
6/2022 | DEM BioPharma | Series A | 0 |
6/2022 | Dren Bio | Series B | 0 |
5/2022 | Pleno | Seed Round | 0 |
5/2022 | Remix Therapeutics | Series B | 0 |
5/2022 | MOMA Therapeutics | Series B | 0 |
5/2022 | Aspen Neuroscience | Series B | 0 |
4/2022 | Pheast Therapeutics | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|